Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
J Chromatogr B Analyt Technol Biomed Life Sci
; 944: 175-81, 2014 Jan 01.
Article
em En
| MEDLINE
| ID: mdl-24316764
Palavras-chave
AHNMD; ANSM; ASM; Advanced systemic mastocytosis; Agence Nationale de Sécurité du Médicament et des produits de santé; CEREMAST; Centre de Référence des Mastocytoses; DMSO; HESI; Human plasma; IS; Internal Standard; LCMS/MS; LLQ; MCL; Midostaurin; QC; RSD; Relative Standard Deviation; SM; SRM; TDM; TKI; TUA; Therapeutic drug monitoring; VEGFR; aggressive systemic mastocytosis; associated clonal hematological non-mast cell lineage disease; dimethylsulfoxide; heated electrospray ionization; lower limit of quantiï¬cation; mast cell leukemia; quality control; selected reaction monitoring; systemic mastocytosis; temporary use authorization; therapeutic drug monitoring; tyrosine kinase inhibitor; vascular endothelial growth factor receptor
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Cromatografia Líquida
/
Monitoramento de Medicamentos
/
Estaurosporina
/
Mastocitose Sistêmica
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article